City of Hope | Strategic Alliance Partners

February 22, 2024

Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.

February 22, 2024

Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.

February 19, 2024

The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.

February 19, 2024

A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.

February 16, 2024

Abhishek Tripathi, MD, discusses the phase 1/2 NEMIO trial of durvalumab/chemotherapy with/without tremelimumab in muscle-invasive bladder cancer.

February 16, 2024

Criteria for identifying patients with MDS most likely to benefit from transplant and choosing the optimal donor source and conditioning regimen on a case-by-case basis.

February 16, 2024

Safety and toxicity data from a clinical trial investigating a novel, precision-engineered allo-HSCT conditioning regimen for older patients with high-risk blood cancers.

February 15, 2024

Joseph Mikhael, MD, discusses treatment advancements and ongoing research in multiple myeloma.

February 13, 2024

Abhishek Tripathi, MD, discusses the significance of data from the phase 3 CheckMate 901 trial in metastatic or unresectable urothelial carcinoma.

February 12, 2024

The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.

February 12, 2024

Comprehensive insights on the adverse effects seen from bispecific antibodies in the treatment of patients with multiple myeloma.

February 09, 2024

This session will focus on considerations and outcomes of allo-HSCT specifically among patients over 55 years of age. The panel will discuss how transplant protocols and supportive care measures can be optimized for this population who are at higher risk of comorbidities, toxicity and poor functional status.

February 09, 2024

An overview of promising novel cellular therapies showing efficacy against hematologic cancers in early-phase clinical trials.

February 09, 2024

The foundation of physician recommendations and medical/regulatory policy will be guided by the outcomes of published clinical research.

February 05, 2024

Multiple myeloma specialists compare step-up dosing practices and provide clinical insights on treating patients with multiple myeloma.

February 05, 2024

Experts on multiple myeloma discuss how real-world evidence informs treatment selection for patients receiving bispecific antibodies.

February 02, 2024

Provide detailed case studies highlighting the development, clinical presentation, multidisciplinary management, and outcomes of patients with acute and chronic GvHD following allo-HSCT.

January 31, 2024

Maurie Markman, MD, discusses the need for a decision support strategy to assist oncologists in treatment selection for patients with actionable mutations.

January 30, 2024

Alexey Danilov, MD, PhD, discusses the use of minimal residual disease to predict outcomes in patients with follicular lymphoma.

January 29, 2024

The innovative “fragmentomics” approach could one day allow doctors to identify cancer in patients sooner than possible today using smaller blood draws.